Recordati announced approval of an eye drop treatment to reduce corneal crystals.
“We are pleased to bring Cystadrops® to patients in the U.S., the first FDA-approved cysteamine eye drop formulation that reduces corneal crystals with a practical four times a day dosing.” -Andrea Recordati, CEO.
The full announcement is available in a press release here.